(MedPage Today) — Wrong-site, wrong-patient procedures are happening more often than suspected despite national quality improvement efforts, and surgeons aren’t the only ones to blame, researchers found.
No Comments »
Filed under: General Health News
ADELPHI, Md. (MedPage Today) — A panel of outside experts has voted 15-1, with one abstention, to recommend that the FDA allow continued use of darbepoetin alpha (Aranesp) for chronic kidney disease patients who are not on dialysis.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA has approved the chronic hepatitis B drug entecavir (Baraclude) for adult patients with the virus and with evidence of liver decompensation, a typically difficult to treat group.
No Comments »
Filed under: General Health News
(MedPage Today) — Another lot of Tylenol — this time 8 Hour Caplets — sold in the U.S. and Puerto Rico has been voluntarily pulled from shelves because of a musty or moldy odor.
No Comments »
Filed under: Pharmacy News
WASHINGTON (MedPage Today) — The FDA has approved the chronic hepatitis B drug entecavir (Baraclude) for adult patients with the virus and with evidence of liver decompensation, a typically difficult to treat group.
No Comments »
Filed under: Pharmacy News
BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.
No Comments »
Filed under: Pharmacy News
Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.
No Comments »
Filed under: Pharmacy News
Acorda Therapeutics, Inc, today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke.
No Comments »
Filed under: Pharmacy News
Adolor Corporation today announced the initiation of a Phase 2 proof-of-concept (PoC) study of ADL5945 in patients suffering from opioid-induced constipation (OIC).
No Comments »
Filed under: Pharmacy News
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company’s investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 [...]
No Comments »
Filed under: Pharmacy News
